Physician profile
Sherin John
NPI 1912583170
$2,189.98
in general payments reported to CMS, 2019-2025
22 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $1,159 · 2023: $634 · 2024: $28.10 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $246.92 | 2022-2025 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $239.11 | 2022-2023 | Eliquis |
| Alnylam Pharmaceuticals INC. | $173.51 | 2022-2023 | Onpattro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.35 | 2022-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $150.16 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.49 | 2022 | |
| Amgen INC. | $131.25 | 2024-2025 | Repatha |
| Pfizer INC. | $129.17 | 2022-2023 | |
| Boston Scientific Corporation | $117.42 | 2021-2023 | Watchman Access System |
| Impulse Dynamics (USA) INC. | $106.42 | 2023 | Optimizer |
| Abbott Laboratories | $81.35 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $76.30 | 2022 | |
| Janssen Pharmaceuticals, INC | $70.65 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $68.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $53.69 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $50.86 | 2023 | |
| Cmp Pharma, INC. | $42.27 | 2022-2023 | Norliqva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.56 | 2022-2023 | Jardiance |
| Daiichi Sankyo INC. | $34.23 | 2022 | |
| Amarin Pharma, INC. | $33.41 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $32.16 | 2023 | Opsumit |
| Sanofi-Aventis U.S. LLC | $22.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherin John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.